Abstract:Despite adherence to the policy of mass measles vaccination in the majority of countries, this infection still remains far from being fully eradicated. Measles outbreaks are reported worldwide, when the vast majority of cases are recorded in subjects of 18—35 years of age. Studies on assessing measles IgG antibody level in different regions of Russia reveal increased percentage of measles seronegative subjects among young adults. Current study was aimed at investigating formation of humoral and cellular immunity after measles vaccination in seronegative adults aged 18 to 30 years old. There were enrolled 50 measles seronegative healthy volunteers aged 18 to 30 years old. Level of anti-measles IgM and IgG antibodies was measured by ELISA (Vector-Best, Russia). Subclasses of measles specific IgG antibodies were analyzed by ELISA, by replacing IgG conjugate for IgG1, IgG2, IgG3, IgG4 conjugates, whereas measles specific IgA antibodies were estimated by ELISA with IgA conjugate (Polygnost, Russia) at a concentration of 1 μg/ml. Antibody avidity was assessed by ELISA (Euroimmun, Germany). Cell-mediated measles immunity was estimated by CD107a surface expression on CD8hi T cell subset stimulated by measles virus-derived antigens. A specific cellular response to measles antigens before vaccination was detected in 50% of examined subjects, whereas 40% samples showed no signs of cellular immune response, with 10% of remaining cases described as equivocal. It was found that 6 weeks after vaccination all vaccinated subjects developed measles specific IgG antibodies at protective level reaching 1.33 (0.85—1.82) IU/ml [Me (LQ—UQ)]. Anti-measles IgA antibodies were of 0.655 (0.423—1.208) IU/ml [Me (LQ—UQ)]. However, no measles specific IgM antibodies were detected 6 weeks after vaccination. In addition, primary type of immune response (dominant low-avidity anti-measles antibodies IgG3 subclass) to measles vaccination was observed in 24 out of 50 subjects, whereas 26 subjects developed secondary type of immune response (high-avidity anti-measles antibodies dominated by IgG1 subclass). A measles specific cellular immune response was observed in 47 of the 50 examined subjects, and in 3 volunteers it was equivocal. Further analysis revealed a cohort of subjects who were not vaccinated against measles (18 subjects), although 60% of them provided medical record on previous dual measles vaccination occurred in childhood. Another cohort consisted of subjects who had medical record of measles vaccination in childhood (32 subjects), but lost protective measles antibodies produced by plasma cells (23 subjects), and memory T cells (3 subjects), or measles antibodies and memory B cells (6 subjects) over time. Such pattern evidences that measles-specific cellular and humoral arms immune responses were developed and maintained independently of each other.

Differential miRNA expression in B cells is associated with inter-individual differences in humoral immune response to measles vaccination

Expression of T Follicular Helper Cells and Its Role in Immune Responses in Children with Measles

Early B cell transcriptomic markers of measles-specific humoral immunity following a 3rd dose of MMR vaccine

Plasma EBV miRNAs Profiles Reveal Potential Biomarkers for clinical prognosis of Acquired Immune Deficiency Syndrome-related Lymphoma

Effect of Lymphocyte miRNA Expression on Influenza Vaccine-Induced Immunity

HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine

Mechanistic insight into immune amnesia and immunity induced by wild-type measles virus compared to live-attenuated measles vaccine

Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy

MicroRNA Differential Expression Profiles in DC after the Stimulation of HBsAg

A Pilot Study of MicroRNAs Expression Profile in Serum and HBsAg Particles

Early human B cell signatures of the primary antibody response to mRNA vaccination

Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types

Comprehensive Analysis of Differentially Expressed Serum Micrornas in Humans Responding to Brucella Infection

Immuno-Microbial Signature of Vaccine-Induced Immunity against SARS-CoV-2

Machine Learning-Based Single Cell and Integrative Analysis Reveals That Baseline mDC Predisposition Correlates With Hepatitis B Vaccine Antibody Response

Dynamics of measles immunity from birth and following vaccination

Differential Expression Of Mirna In The Peripheral Blood Mononuclear Cells In Myasthenia Gravis With Muscle-Specific Receptor Tyrosine Kinase Antibodies

Immunogenicity of a peptide-based vaccine for measles: a pilot evaluation in a mouse model

Immunological landscape of human lymphoid explants during measles virus infection

Formation of humoral and cellular immunity to measles vaccine in adults